Start Here
Compare Providers
Novo Nordisk Hims breakup timeline and Wegovy access checks

On this page

    Novo Nordisk and Hims: Wegovy Access Timeline and What Patients Should Check

    Ryan Lafayette
    Edited By Ryan Lafayette
    Updated Apr 28, 2026
    Source-Checked Editorial

    Source-checked editorial. Edited by Ryan Lafayette. This guide reports public-source information only and is not medical advice.

    Meet the Editor See How We Verify

    Updated April 2026: This article explains a market and access timeline. It is not medical advice. Review personal treatment decisions with a licensed clinician.

    If the Novo Nordisk Hims breakup changed your Wegovy or GLP-1 access, do not assume the next listing is a direct substitute. Check current medication category, prescription status, records, renewal timing, and coverage before switching providers or changing programs.

    What changed after the Novo Nordisk Hims breakup?

    The short version is that this was not one static breakup. The relationship between Hims & Hers and Novo Nordisk has shifted multiple times over the past year:

    • April 2025: Hims & Hers and Novo Nordisk announced an initial Wegovy access collaboration.1
    • June 2025: Novo Nordisk terminated the collaboration, stating in a press release that the decision was due to concerns over what Novo alleged was “illegal mass compounding and deceptive marketing” by Hims.2
    • February 2026: Novo Nordisk filed a lawsuit against Hims alleging patent infringement related to compounded medications.8
    • March 2026: The companies ended the lawsuit and announced a new collaboration. Hims & Hers announced a strategic shift for its US weight loss business, stating it would stop advertising compounded GLP-1 offerings and provide an opportunity for existing patients to transition to FDA-approved medicines.37 Later that month, Hims announced that eligible customers could access Novo Nordisk’s FDA-approved GLP-1 options through their platform.4

    Why the old breakup framing is not enough

    A June 2025 breakup article can help readers understand why access changed at that time, but it is not enough for a 2026 reader deciding what to do now. The March 2026 settlement means Hims is pivoting toward FDA-approved branded Wegovy. Current access may depend on updated Hims offerings, Novo Nordisk terms, insurance rules, membership fees, pharmacy fulfillment, and whether a clinician thinks a specific medication option is appropriate.

    Use this page as an event-specific case study. For broader access disruptions that are not specifically about Hims, use the GLP-1 access-change guide first.

    If this affected your current care, check five things

    1. Current supply: How much medication do you have left, and when would the next refill normally be due?
    2. Prescription status: Is there an active prescription, a pending clinician review, or a new visit requirement to transition from a compounded option to a branded medication?
    3. Medication category: Is the listing an FDA-approved brand option, an insurance-routed fill, an out-of-pocket brand option, or a different category?
    4. Records: Can the next clinician see your dose history, labs, side-effect notes, and prior authorization context?
    5. Billing: Is your current Hims or telehealth plan renewing before the new option is clear? Branded medications often have different out-of-pocket costs than compounded options.

    Request records before a provider transfer stalls

    If you are moving from Hims to another prescriber, or transitioning to a new care team within a telehealth platform, the clinical team may need more than your memory of the dose. Prior dose history, refill timing, labs, side effects, and insurance paperwork can affect how smoothly the transition is reviewed.

    Use the GLP-1 medical records request checklist before the old portal becomes harder to access or the new team has to rebuild your history from scratch.

    Check cancellation timing before you leave a paid plan

    Access changes and billing changes do not always happen on the same day. If you are leaving a paid telehealth program because of the shift away from compounded options, confirm the renewal date, cancellation cutoff, refund boundary, and confirmation proof before assuming the account will stop billing automatically.

    Use the GLP-1 telehealth cancellation checklist if the next charge could hit before your new provider or refill plan is ready.

    How to compare current Hims or telehealth listings

    • Confirm the medication category (FDA-approved brand vs. compounded) and whether the medication cost is separate from the membership cost.
    • Check whether the prescriber can serve your state and whether the prescription can be filled or delivered where you live.
    • Ask what happens if insurance authorization is delayed, denied, or needs renewal.
    • Review refill cadence, follow-up requirements, shipment timing, and support channels.
    • Do not treat a headline price as proof that the option is available, equivalent, or clinically appropriate for you.

    Where to go next

    This page covers the Hims and Novo Nordisk timeline. It is not the main guide for every GLP-1 access disruption. Use these routes depending on the real blocker:

    • GLP-1 access changed: use this broader guide when the issue is compounding, provider, pharmacy, price, or program disruption.
    • Insurance & Coverage: use this if prior authorization, denial, plan rules, or appeal documentation is the blocker.
    • Switching & Refills: use this if the practical problem is refill continuity, pharmacy timing, or a provider transfer.
    • GLP-1 provider pricing: use this if the problem is membership fees, medication cost, renewal terms, or recurring monthly math.

    FAQ

    Did Novo Nordisk and Hims only break up?

    No. While Novo Nordisk terminated an initial collaboration in June 2025 and filed a lawsuit in February 2026, the companies reached a settlement in March 2026. Hims announced a new collaboration to offer FDA-approved Novo Nordisk GLP-1s and a strategic shift away from advertising compounded weight-loss options.1237

    Does this mean I should switch medication?

    No article can answer that for you. Medication choice, dose changes, stopping, restarting, and side effects should be reviewed with a licensed clinician who knows your history.

    What if I only need to avoid a refill gap?

    Start with supply, prescription status, records, whether the next refill can reach you on time, and appointment timing. If you are moving care teams, request records before the new team has to make decisions without your prior file.

    Disclaimer: This article is intended for informational purposes. It is not medical advice. Consult a healthcare professional for guidance on treatment, coverage, or medication changes.

    References

    1. Hims & Hers. Hims & Hers and Novo Nordisk Team Up to Expand Affordable Access to Care. April 29, 2025. View source
    2. Novo Nordisk press release via BioSpace. Novo Nordisk terminates collaboration with Hims & Hers Health, Inc. June 23, 2025. View source
    3. Hims & Hers. Hims & Hers Announces Strategic Shift for US Weight Loss Business. March 9, 2026. View source
    4. Hims & Hers. Novo Nordisk’s FDA-Approved GLP-1s Now Available With Hims & Hers. March 26, 2026. View source
    5. U.S. Food and Drug Administration. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Content current as of February 4, 2026. View source
    6. U.S. Food and Drug Administration. FDA Intends to Take Action Against Non-FDA-Approved GLP-1 Drugs. View source
    7. Associated Press. Hims & Hers Health and Novo Nordisk end lawsuit over weight loss medications, enter collaboration. March 2026. View source
    8. Novo Nordisk. News Archive. February 9, 2026. View source